Boston Scientific (BSX) Q2 2025 10-Q Quarterly Report
Filed: Aug 1, 2025Period ending Jun 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR Boston Scientific (BSX) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 1, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Boston Scientific Q2 2025 10-Q Analysis
Management Discussion & Analysis
- • No specific quarterly revenue or YoY change figures provided in excerpt
- • No profitability or margin % figures disclosed in excerpt
Risk Factors
- • No new or changed risk factors disclosed this quarter; risk section references most recent 10-K
- • Carried-forward regulatory risk: ongoing compliance with Sarbanes-Oxley Act Sections 302 and 906 certifications by CEO and CFO
Boston Scientific Q2 2025 Quarterly FinancialsXBRL
Revenue
$5.1B
▲ +22.8% YoY▲ +8.5% QoQ
Net Income
$797M
▲ +146.0% YoY▲ +18.2% QoQ
Gross Margin
67.6%
▼ -152bp YoY▼ -120bp QoQ
Operating Margin
16.2%
▲ +356bp YoY▼ -357bp QoQ
Net Margin
15.7%
▲ +789bp YoY▲ +129bp QoQ
EPS (Diluted)
$0.53
▲ +140.9% YoY▲ +17.8% QoQ
Operating Cash Flow
$1.3B
▲ +58.2% YoY▲ +137.7% QoQ
Source: XBRL data from Boston Scientific Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Boston Scientific Quarterly Reports
Get deeper insights on Boston Scientific
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.